Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-06-14
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotech that uses its Recursion OS, automated labs, and proprietary data to discover and develop medicines internally and with pharmaceutical partners.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Could Unlock Platform Value
This is a cash-backed option on one hard question: can AI-driven discovery produce regulatory-grade medicines often enough to deserve a platform premium? One credible product path plus more recurring partner economics could drive a meaningful rerating, but validation and financing remain the gates.

Analysis

Thesis
Recursion is a leveraged bet that AI makes hypothesis generation cheap while verified wet-lab data, automated experimentation, and downstream drug rights stay scarce; if REC-4881 earns a credible late-stage path and partner programs convert into recurring economics, the stock can rerate from cash-backed skepticism to a hybrid product-plus-platform biotech by 2031.
Last Economy Alignment
Positive because cheaper cognition helps Recursion's private data-and-lab loop more than it hurts pricing. The cap is clinical proof and funding, not software seat compression or agent bypass.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 5 most recent analyses)
Reasoning
I am underwriting a quality shift, not just more experiments. One credible rare-disease product path, one additional internal proof point, and more recurring partner economics could move Recursion from a lumpy collaboration story to a hybrid platform biotech. That deserves a better valuation than today's skepticism, but not a pure software or fully de-risked commercial-biotech premium because proof and financing remain incomplete.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is translation, not imagination. Recursion already has the AI, data, and lab stack; what it still must prove is that this stack repeatedly creates human-relevant clinical results fast enough to earn a premium valuation before dilution becomes the bridge to that proof.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.43
They own automated labs, private biology data, and the drug rights that come from turning that data into medicines, so cheaper AI helps them run the loop faster. The risk is simple: if faster discovery still does not produce human proof before cash runs down, the advantage will look smaller than advertised.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case